A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting

References

• Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234.
   PubMed Web of Science ®Google Scholar
• AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Hyman L, EMGT Group, et al. Intraocular pressure reduction with a fixed treatment protocol in the early manifest glaucoma trial. Acta Ophthalmol. 2011;89(8):749–754.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study. Arch Ophthalmol. 2002;120(6):701–713.
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon MO, Gao F, Ocular Hypertension Treatment Study Group, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010;128(3):276–287.
   PubMedGoogle Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.
   PubMed Web of Science ®Google Scholar
• Anderson DR, Normal Tension Glaucoma Study. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14(2):86–90.
   PubMedGoogle Scholar
• American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern; 2015 [cited 2020 Sept 9]. Available from: https://www.aaojournal.org/article/S0161-6420(15)01276-2/pdf.
   Google Scholar
• Schwartz GF, Patel A, Naik R, et al. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. Ophthalmol Glaucoma. 2020. DOI:10.1016/j.ogla.2020.09.002
   PubMedGoogle Scholar
• RHOPRESSA [prescribing information]. Irvine, CA: Aerie Pharmaceuticals, Inc.; 2019.
   Google Scholar
• Ren R, Li G, Le TD, et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197–6209.
   PubMed Web of Science ®Google Scholar
• Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016;787:20–31.
   PubMed Web of Science ®Google Scholar
• Wang RF, Williamson JE, Kopczynski C, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24:51–54.
   PubMed Web of Science ®Google Scholar
• Kazemi A, McLaren JW, Kopczynski CC, et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380–386.
   PubMed Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. ROCKET-1 and ROCKET-2 study groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–127.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248–257.
   PubMed Web of Science ®Google Scholar
• Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2(5):280–289.
   PubMedGoogle Scholar
• Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327–338.
   PubMedGoogle Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13(2):130–136.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Singh K. Maximal glaucoma therapy. J Glaucoma. 2001;10(5 Suppl 1):S73–S75.
   PubMed Web of Science ®Google Scholar
• Tanna AP, Lin AB. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr Opin Ophthalmol. 2015;26(2):116–120.
   PubMed Web of Science ®Google Scholar
• Ustaoglu M, Shiuey E, Sanvicente C, et al. The efficacy and safety profile of netarsudil 0.02% in glaucoma treatment: real-world outcomes. Invest Ophthalmol Vis Sci. 2019;60:2393.
   Web of Science ®Google Scholar
• Tang M, Prager A, Pleet A, et al. Retrospective analysis of the efficacy and safety of netarsudil in clinical practice. Invest Ophthalmol Vis Sci. 2020;61:1241.
   Google Scholar
• Meshkin RS, Klug E, Chachanidze MM, et al. Assessing netarsudil’s IOP lowering effect when used as a 3rd, 4th, or 5th + agent. Poster presented at AAO 2020 – American Academy of Ophthalmology Annual Meeting; 2020 Nov 14–17; Las Vegas, NV. Poster PO177.
   Google Scholar
• Musch DC, Gillespie BW, Niziol LM, CIGTS Study Group, et al. Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study. Ophthalmology. 2011;118(9):1766–1773.
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Balaszi AG, Canadian Glaucoma Study Group, et al. Canadian glaucoma study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030–1036.
   PubMedGoogle Scholar
• Jammal AA, Thompson AC, Mariottoni EB, et al. Impact of intraocular pressure control on rates of retinal nerve fiber layer loss in a large clinical population. Ophthalmology. 2021;128(1):48–57.
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):40–51.
   PubMed Web of Science ®Google Scholar
• Singh IP, Fechtner RD, Myers JS, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29(10):878–884.
   PubMed Web of Science ®Google Scholar
• Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620–1631.
   PubMed Web of Science ®Google Scholar
• Woolf S, Bahr T, Waldman C. The addition of latanoprostene bunod or netarsudil to glaucoma patients on standard maximum medical therapy. Invest Ophthalmol Vis Sci. 2020;61:1224.
   Google Scholar
• Mehta P, Kaplowitz K, Lenoci J, et al. IOP lowering efficacy of adjunctive netarsudil (Rhopressa): a retrospective chart review. Invest Ophthalmol Vis Sci. 2020;61:1237.
   Google Scholar
• Lin MM, Moster SJ, Zheng CX, et al. Netarsudil's effect in eyes with a history of selective laser trabeculoplasty. Ophthalmol Glaucoma. 2020;3(4):306–308.
   PubMedGoogle Scholar